Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer-Reference-Cited by-同舟云学术

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

Published:2017-02-16 Issue:6 Volume:143 Page:1053-1059
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Okusaka Takuji^ORCID, ,Miyakawa H.,Fujii H.,Nakamori S.,Satoh T.,Hamamoto Y.,Ito T.,Maguchi H.,Matsumoto S.,Ueno H.,Ioka T.,Boku N.,Egawa S.,Hatori T.,Furuse J.,Mizumoto K.,Ohkawa S.,Yamaguchi T.,Yamao K.,Funakoshi A.,Chen J. S.,Cheng A. L.,Sato A.,Ohashi Y.,Tanaka M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-017-2349-y.pdf

Reference7 articles.

1. Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29–41

2. Burris HA 3rd, Moore MJ, ersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

3. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

4. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York, p 14

5. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis;Heliyon;2024-04

2. Metastatic Pancreatic Cancer: Where Are We?;Oncology Reviews;2024-01-18

3. S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL;Zeitschrift für Gastroenterologie;2022-11

4. Phase II Study of SOXIRI (S-1/Oxaliplatin/Irinotecan) Chemotherapy in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Prospective Study (Preprint);2022-06-21

5. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma;Scientific Reports;2022-06-15